Highlights Endonovo Therapeutics, Inc.

Equities

ENDV

US29272H3003

Market Closed - OTC Markets Other stock markets 03:46:23 2024-07-02 pm EDT			5-day change	1st Jan Change
0.0009 ^USD	-16.67%		-18.18%	-89.66%

2023	Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Dec. 29	CI
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	23-10-12	CI
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	23-08-22	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division	23-06-07	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration	23-05-02	CI
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment	23-04-25	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Endonovo Therapeutics, Inc. Announces Final Stages to Receive Taiwan FDA License to Distribute in Taiwan	23-03-23	CI
Endonovo Announces Distribution Agreement with Academy Medical	23-03-06	CI
Endonovo Partners with International Distributor for SofPulse Line	23-01-26	CI
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as A Listed Public Company	23-01-09	CI
Endonovo Therapeutics, Inc. agreed to Spin-Off Medical Device Division of Endonovo Therapeutics.	23-01-08	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
Endonovo Therapeutics, Inc. entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star.	22-09-26	CI
Endonovo Therapeutics Releases Comparative Analysis Demonstrating	22-07-28	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-19	CI
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products	22-04-25	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Endonovo Therapeutics, Inc.

Equities

ENDV

US29272H3003

Highlights

Filters